{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T02:10:27Z","timestamp":1710123027723},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1097\/mnm.0b013e3282f1ac59","type":"journal-article","created":{"date-parts":[[2009,3,3]],"date-time":"2009-03-03T23:21:41Z","timestamp":1236122501000},"page":"943-950","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of different beta-counting systems involved in 90Y-Zevalin quality control"],"prefix":"10.1097","volume":"28","author":[{"given":"Nicoletta","family":"Urbano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Modoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-11-20210212","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"R2-11-20210212","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"R3-11-20210212","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1200\/JCO.1999.17.12.3793","article-title":"Phase I\/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma","volume":"7","author":"Witzig","year":"1999","journal-title":"J Clin Oncol"},{"key":"R4-11-20210212","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1182\/blood.V99.12.4336","article-title":"Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial","volume":"99","author":"Wiseman","year":"2002","journal-title":"Blood"},{"issue":"suppl 17","key":"R5-11-20210212","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1053\/j.seminoncol.2003.10.007","article-title":"Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma","volume":"30","author":"Witzig","year":"2003","journal-title":"Semin Oncol"},{"key":"R6-11-20210212","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1089\/cbr.2005.20.185","article-title":"Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin\u00ae) induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"20","author":"Wiseman","year":"2005","journal-title":"Cancer Biother Radiopharm"},{"key":"R7-11-20210212","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/10428190500376076","article-title":"Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma","volume":"47","author":"Emmanouilides","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"R8-11-20210212","first-page":"574","article-title":"IDEC-Y2B8: a 90Y-labeled anti-CD20 monoclonal antibody conjugated to MX-DTPA, a high-affinity chelator for yttrium Abstract","volume":"40","author":"Chinn","year":"1999","journal-title":"Proc Am Assoc Clin Res"},{"key":"R9-11-20210212","first-page":"503","article-title":"DTPA-coupled antibodies labelled with yttrium-90","volume":"26","author":"Hnatowich","year":"1985","journal-title":"J Nucl Med"},{"key":"R10-11-20210212","first-page":"35","article-title":"Distribution in rats after intravenous injection of 88Y compounds (Author's translation)","volume":"20","author":"Kutzner","year":"1981","journal-title":"Nuklearmedizin"},{"key":"R11-11-20210212","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0021-9258(18)55794-X","article-title":"The skeletal deposition of yttrium","volume":"195","author":"MacDonald","year":"1952","journal-title":"J Biol Chem"},{"key":"R12-11-20210212","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.nucmedbio.2004.03.008","article-title":"Reduction of skeletal accumulation of radioactivity by co-injection of DTPA in [90Y-DOTA0,Tyr3] octreotide solutions containing free 90Y3+","volume":"31","author":"Breeman","year":"2004","journal-title":"Nucl Med Biol"},{"issue":"S1","key":"R13-11-20210212","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1053\/j.seminoncol.2005.01.013","article-title":"90Y-Ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma","volume":"32","author":"Grillo-Lopez","year":"2005","journal-title":"Semin Oncol"},{"key":"R14-11-20210212","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.2003.08.043","article-title":"Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low grade, follicular, or transformed non-Hodgkin's lymphoma","volume":"21","author":"Witzig","year":"2003","journal-title":"J Clin Oncol"},{"key":"R15-11-20210212","first-page":"465","article-title":"Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials","volume":"44","author":"Wiseman","year":"2003","journal-title":"J Nucl Med"},{"key":"R16-11-20210212","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1089\/1084978041979535","article-title":"Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia","volume":"19","author":"Schilder","year":"2004","journal-title":"Cancer Biother Radiopharm"},{"key":"R17-11-20210212","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00006231-200502000-00014","article-title":"A comparison of techniques for analysing 90Y-Zevalin thin-layer chromatography plates","volume":"28","author":"O'Brien","year":"2005","journal-title":"Nucl Med Commun"},{"key":"R18-11-20210212","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0969-8051(97)00055-3","article-title":"The use of electronic autoradiography in radiopharmacy","volume":"24","author":"Decristoforo","year":"1997","journal-title":"Nucl Med Biol"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00006231-200712000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T01:37:09Z","timestamp":1710121029000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006231-200712000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0b013e3282f1ac59","relation":{},"ISSN":["0143-3636"],"issn-type":[{"value":"0143-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}